Innate Pharma (IPHA) Intangibles (2017 - 2024)
Innate Pharma posted quarterly Intangibles of $128149.6 for Q2 2024, down 86.97% year-on-year from $983298.7 in Q3 2023, and down 71.37% on a QoQ basis from $447591.0 in Q4 2023.
Innate Pharma (IPHA) has 8 years of Intangibles data on file, last reported at $128149.6 in Q2 2024.
- For the quarter ending Q2 2024, Intangibles fell 86.97% year-over-year to $128149.6; the trailing twelve-month figure through Jun 2024 stood at $128149.6 (down 86.97% YoY), and the FY2023 full-year result was $447591.0, down 71.81% from the prior year.
- Intangibles for Q2 2024 stood at $128149.6, down from $447591.0 in the prior quarter.
- Across five years, Intangibles topped out at $95.2 billion in Q2 2020 and bottomed at $128149.6 in Q2 2024.
- The 5-year median for Intangibles is $46.2 million (2022), against an average of $10.6 billion.
- Peak annual rise in Intangibles reached 8.4% in 2021, while the deepest fall reached 99.94% in 2021.
- A 5-year view of Intangibles shows it stood at $55.2 million in 2020, then declined by 8.4% to $50.6 million in 2021, then sank by 96.86% to $1.6 million in 2022, then plunged by 71.81% to $447591.0 in 2023, then plunged by 71.37% to $128149.6 in 2024.
- The last three Intangibles figures came in at $128149.6 (Q2 2024), $447591.0 (Q4 2023), and $983298.7 (Q2 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - | 4.41 Mn |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - | - |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | 11,640.44 |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - | 30.30 Mn |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn | 418.50 Mn |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn | 1.29 Bn |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn | - |
| 10 | Innate Pharma | 199.64 Mn | 199.64 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 128,149.62 |
| Dec 31, 2023 | 447,591.00 |
| Jun 30, 2023 | 983,298.73 |
| Dec 31, 2022 | 1.59 Mn |
| Jun 30, 2022 | 46.16 Mn |
| Dec 31, 2021 | 50.55 Mn |
| Jun 30, 2021 | 54.42 Mn |
| Dec 31, 2020 | 55.19 Mn |
| Jun 30, 2020 | 95.22 Bn |
| Dec 31, 2019 | 107.33 Mn |
| Dec 31, 2018 | 96.48 Mn |
| Dec 31, 2017 | 54.39 Mn |